ENGLEWOOD, Colo., Feb. 24, 2021 /PRNewswire/ -- Ampio
Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company
focused on the advancement of immunology-based therapies for
prevalent inflammatory conditions, today announced it will host a
conference call to discuss the financial results for the year ended
December 31, 2020 and provide a
corporate business update on Wednesday,
March 3, 2021 at 4:30pm EST/
1:30pm PST.
Conference Call & Webcast:
Wednesday, March 3, 2021,
4:30pm EST / 1:30pm PST
Domestic: 888-506-0062
Conference ID # 441054
International: 973-528-0011
Conference ID # 441054
Webcast
Link: https://www.webcaster4.com/Webcast/Page/2569/39961
The conference call will also be available from the Investor
Relations section of the Company's website at www.ampiopharma.com
and will be archived there shortly after the live event.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage
biopharmaceutical company primarily focused on the development of
Ampion, our product candidate, to treat prevalent inflammatory
conditions for which there are limited treatment options. Ampio's
lead drug, Ampion, is backed by an extensive patent portfolio with
intellectual property protection extending through 2035 and will be
eligible for 12-year FDA market exclusivity upon approval as a
novel biologic under the biologics price competition and innovation
act ("BPCIA").
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as
well as those associated with regulatory approvals and other FDA
decisions, the Biological License Application ("BLA"), the ability
of Ampio to enter into partnering arrangements,
clinical trials and decisions and changes in business
conditions and similar events, the ability to receive regulatory
approval to conduct clinical trials, that Ampion may be used to
treat ARDS induced by COVID-19, all of which are inherently subject
to various risks and uncertainties. The risks and uncertainties
involved include those detailed from time to time in Ampio's
filings with the Securities and Exchange Commission, including
without limitation, under Ampio's Annual Report on Form 10-K and
other documents filed with the Securities and Exchange Commission.
Ampio undertakes no obligation to revise or update these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Company Contacts
Investor Relations
Joe Hassett
joeh@gregoryfca.com
484-686-6600
Media Contact
Katie
Kennedy
katie@gregoryfca.com
610-731-1045
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-to-report-annual-2020-financial-results-and-provide-corporate-business-update-301234647.html
SOURCE Ampio Pharmaceuticals, Inc.